Business Context and Reporting Period
This Form 8-K, filed on February 19, 2020, by Tocagen Inc. (TOCA), announces the entry into a definitive merger agreement with Forte Biosciences, Inc. (Forte), a clinical-stage biopharmaceutical company. The transaction involves a reverse merger where Forte will become a wholly-owned subsidiary of Tocagen. The filing also details a concurrent pre-closing financing arrangement and support agreements from key stakeholders.
Key Financial Metrics and Transaction Terms
- Pre-Closing Financing: Forte has secured approximately $14,000,000 in proceeds from investors immediately prior to the closing. This includes the purchase of Forte common stock at $1.0769 per share and warrants.
- Valuation: The warrant exercise price in the financing values the combined parent company at $120,000,000 immediately following the effective date.
- Ownership Structure (Post-Closing):
- Forte equityholders (including pre-closing investors): Expected to own approximately 74.5% of the combined company.
- Tocagen equityholders: Expected to own approximately 25.5% of the combined company.
- Pre-closing investors: Expected to own approximately 18.5% of the combined company.
- Liquidity Conditions: Closing is contingent on Tocagen's net cash being between $3,000,000 and $10,000,000 (specifically $7.5M-$10M for the 74.5% ownership calculation).
- Termination Fees:
- Standard termination: $500,000 (Tocagen to Forte) or $1,000,000 (Forte to Tocagen).
- Board recommendation change by Forte: $3,000,000 payable by Forte to Tocagen.
- Superior offer by Tocagen: $750,000 payable by Tocagen to Forte.
- Failure of Tocagen stockholder approval: Up to $250,000 expense reimbursement by Tocagen to Forte.
Material Changes and Corporate Actions
The filing represents a material change in Tocagen's corporate structure and business strategy. Key changes include:
- Leadership Change: Paul Wagner (Forte) will serve as the President and CEO of the combined company.
- Board Composition: The new board will consist of 8 directors: 6 designated by Forte and 2 by Tocagen.
- Reverse Stock Split: Tocagen stockholders must approve a reverse stock split (ratio 1-for-8 to 1-for-12) to maintain Nasdaq listing standards.
- Asset Divestment: Tocagen may sell, transfer, or divest certain assets unless mutually agreed otherwise.
- Support Agreements: Tocagen officers/directors covering ~6% of shares and Forte stakeholders covering ~95% of shares have agreed to vote in favor of the merger.
Guidance, Risks, and Contingencies
Conditions Precedent: The merger is subject to stockholder approval from both companies, regulatory approvals, the effectiveness of the Form S-4 registration statement, and the successful closing of the $14 million pre-closing financing.
Forward-Looking Risks: The filing highlights significant uncertainties, including:
- Failure to complete the merger or satisfy closing conditions.
- Risks related to Forte's clinical development pipeline, specifically the product candidate FB-401.
- Timing of clinical trials, data availability, and regulatory approvals (IND/NDA).
- Future capital requirements and the need for additional financing post-merger.
- Ability to maintain Nasdaq listing compliance.
Management Commentary: The transaction is intended to qualify as a tax-free reorganization. Management emphasizes that the combined entity will leverage Tocagen's public platform and Forte's clinical-stage assets.
Investor Verification Checklist
- Verify the final terms of the Form S-4 proxy statement and prospectus before voting.
- Confirm the successful closing of the $14,000,000 pre-closing financing by Forte.
- Monitor the outcome of the Tocagen stockholder vote regarding the reverse stock split and asset divestment.
- Review the specific details of the asset divestment to understand what assets Tocagen is retaining versus selling.
- Assess the clinical status and regulatory pathway of Forte's lead candidate, FB-401, as this drives the post-merger valuation.
- Check the final net cash position of Tocagen at closing to ensure it meets the $3,000,000 minimum threshold.